Ratings by Stifel (Adam Walsh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/18/2020 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 4/20/2020 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2020 | Reata Pharmaceuticals | RETA | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2020 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2020 | Galmed Pharmaceuticals | GLMD | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2020 | Galapagos NV | GLPG | Maintain | Buy (N/A) |
|
Details | ||
| 2/20/2020 | Reata Pharmaceuticals | RETA | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2020 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 12/18/2019 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2019 | Reata Pharmaceuticals | RETA | Maintain | Buy (N/A) |
|
Details | ||
| 10/16/2019 | Reata Pharmaceuticals | RETA | Maintain | Buy (N/A) |
|
Details | ||
| 9/27/2019 | Concert Pharmaceuticals | CNCE | Downgrade | Hold (Buy) |
9.87 (8.37) |
-15.2% | Details | |
| 9/18/2019 | Durect Corp | DRRX | Maintain | Hold (N/A) |
|
Details | ||
| 9/9/2019 | PhaseBio Pharmaceuticals Inc. | PHAS | Maintain | Buy (N/A) |
|
Details | ||
| 6/18/2019 | PhaseBio Pharmaceuticals Inc. | PHAS | Maintain | Buy (N/A) |
|
Details | ||
| 5/9/2019 | Protagonist Therapeutics | PTGX | Upgrade | Buy (Hold) |
8.98 (92.09) |
925.5% | Details | |
| 4/9/2019 | PhaseBio Pharmaceuticals Inc. | PHAS | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2019 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2019 | Verona Pharma | VRNA | Maintain | Hold (N/A) |
|
Details | ||
| 2/11/2019 | FibroGen | FGEN | New Coverage | Buy (N/A) |
55.90 (9.71) |
-82.63% | Details | |
| 1/2/2019 | Verona Pharma | VRNA | New Coverage | Hold (N/A) |
9.65 (106.91) |
1007.88% | Details | |
| 11/12/2018 | PhaseBio Pharmaceuticals Inc. | PHAS | New Coverage | Buy (N/A) |
5.01 (0.07) |
-98.6% | Details | |
| 11/6/2018 | Equillium | EQ | New Coverage | Buy (N/A) |
15.03 (1.77) |
-88.22% | Details | |
| 10/26/2018 | Ultragenyx Pharma | RARE | Maintain | Buy (N/A) |
|
Details | ||
| 10/22/2018 | GTX Inc. | GTXI | Maintain | Hold (N/A) |
|
Details | ||
| 9/21/2018 | GTX Inc. | GTXI | Downgrade | Hold (Buy) |
23.29 (1.20) |
-94.85% | Details | |
| 8/28/2018 | Ultragenyx Pharma | RARE | Maintain | Buy (Buy) |
|
Details |
